Quoin Pharmaceuticals Ltd. (QNRX) filings document a State of Israel registrant whose Nasdaq-listed American Depositary Shares each represent 35 ordinary shares. Recent 8-K reports record quarterly and annual financial results, Regulation FD disclosures and material events tied to the company's rare-disease drug-development programs.
The filing record includes disclosures about QRX003 regulatory designations for Netherton Syndrome, QRX009 topical rapamycin delivery technologies, capital-structure matters and board compensation arrangements. These reports also identify the ADS and ordinary-share structure and exchange listing for QNRX securities.
Quoin Pharmaceuticals Ltd. registered up to $150,000,000 in aggregate offering price of ordinary shares represented by ADSs, warrants, subscription rights, debt securities and units for one or more offerings. No securities may be sold until the registration statement is effective, and a sale requires an applicable prospectus supplement. While public float remains below $75.0 million, public primary sales are limited to no more than one-third of public float in any 12-month period; Quoin reported no sales under this limit during the 12 calendar months prior to and including October 27, 2026. Net proceeds are currently intended primarily for working capital and general corporate purposes, subject to any supplement or free writing prospectus.
Quoin describes itself as a late-stage clinical specialty pharmaceutical company with no commercialized products or product revenue to date. Its lead candidate QRX003 is entering pivotal registrational clinical testing for Netherton Syndrome; eight pediatric patients are in a Compassionate Use program, with three additional patients expected to enroll in 2026. The FDA cleared the Peeling Skin Syndrome IND on July 9, 2026, and the company plans to initiate a Phase 2/3 study by the end of 2026.
Quoin Pharmaceuticals Ltd. (QNRX) director Dennis Langer’s amended ownership report corrects an inadvertent overstatement of his direct holdings. The corrected entry lists 49,687 ADSs directly held following the reported transaction dated August 27, 2026.
Quoin Pharmaceuticals Ltd. announced publication of a peer-reviewed paper on QRX003, its investigational topical lotion for Netherton Syndrome, including a pediatric compassionate-use case report. After six weeks of once-daily whole-body treatment added to existing care, the patient’s IGA score changed from 4 (severe) to 1 (almost clear), and the itch score from 5 to 1. By eight months, the scores were 0 (clear) and 0 (no itch). Over 21 months, the patient was mostly at IGA 0, with occasional IGA 1; no adverse events considered treatment-related were reported.
Quoin also described interim results from its Phase 2/3 study: 4 of 6 participants completing 12 weeks (66.7%) achieved at least a 1-grade IGA improvement (p=0.0087 versus a pre-specified alpha of 0.0215). The company expects to complete recruitment of all 20 participants by the end of 2026 and report topline data in the second quarter of 2027. The case report describes one patient; the authors say ongoing trials will further evaluate QRX003’s safety and efficacy.
Quoin Pharmaceuticals Ltd. (QNRX) announced that the European Medicines Agency granted its lead product candidate QRX003 Orphan Drug Designation in Europe for Peeling Skin Syndrome. The designation provides incentives including scientific advice on study protocols, fee reductions and access to EU grants. If the EMA approves QRX003 for marketing, it will receive 10 years of market exclusivity in Europe for similar medicines treating the condition. Quoin intends to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year end. QRX003 is also being evaluated in late-stage clinical trials for Netherton Syndrome. Quoin described the designation as QRX003’s eighth important regulatory milestone across both indications.
Quoin Pharmaceuticals Ltd. (QNRX) is the issuer named in an amended Schedule 13G reporting 211,538 American Depositary Shares (ADS), or 4.4% of the class. Each ADS represents 35 ordinary shares. Ikarian Capital, LLC and Neil Shahrestani report shared voting and dispositive power over the ADS, with no sole voting or dispositive power. The ADS are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts; Ikarian Capital serves as investment manager to the Fund and sub-adviser to the accounts, and Shahrestani may be deemed to indirectly beneficially own securities attributed to Ikarian Capital. The 4.4% figure is based on 4,804,161 ADS outstanding as of September 16, 2026. The Fund and managed accounts disclaim beneficial ownership of securities held by one another, and the reporting persons state that the filing is not an admission of beneficial ownership.
Quoin Pharmaceuticals Ltd. is asking shareholders to amend the beneficial ownership and corresponding voting-power limits on warrants from its private placements consummated on October 14, 2025 and August 31, 2026. If approved, holders could, upon written notice, set limits from 4.99% to any percentage not exceeding 9.99%.
An increase would take effect on the 61st day after notice; holders could also decrease the limit applicable to any portion of their warrants. The board recommends a “FOR” vote on both the amendment and a proposal to adjourn if needed to solicit more votes. Quoin says shares issued upon warrant exercise would dilute existing shareholders’ voting power and economic rights, and sales of resulting ADSs could affect market prices.
The special meeting is scheduled for November 12, 2026, with a record date of September 23, 2026. If the ownership-limit proposal fails, the limits remain at 4.99%; holders reaching that threshold may need to sell shares before exercising more warrants, which could slow exercises and delay proceeds to Quoin.
Quoin Pharmaceuticals Ltd. (QNRX) registered for resale up to 9,371,895 ADSs representing 328,016,325 ordinary shares held by selling shareholders; Quoin is not selling ADSs in this prospectus. Selling shareholders receive resale proceeds. Quoin will not receive proceeds from those sales, but could receive up to approximately $19.1 million, less placement agent fees, if all Ordinary Warrants are exercised for cash.
The private placement closed on August 31, 2026, with approximately $30.8 million in gross proceeds and approximately $29.0 million in net proceeds. ADSs covered but not currently outstanding represent approximately 144.2% of the 4,804,161 ADSs outstanding as of September 16, 2026; Quoin says actual issuance may be less than the amount registered. Ordinary Warrants have a $6.10-per-ADS exercise price and expire at the earlier of five years from closing or 30 days after public announcement that the QRX003-004 trial's primary endpoint has been met. The incorporated 2025 audit report includes an explanatory paragraph concerning Quoin's ability to continue as a going concern.
Quoin Pharmaceuticals Ltd. (QNRX) is calling a special general meeting on November 12, 2026 to ask shareholders to approve raising the beneficial ownership cap on certain private placement investors from 4.99% to up to 9.99% of outstanding ordinary shares (including ADSs) for both voting and reporting purposes.
The change would apply to warrants issued in private placements completed on October 14, 2025 and August 31, 2026, allowing holders, on written notice and after 61 days, to increase their individual limits, which may facilitate warrant exercises and capital inflows but would dilute existing holders and could concentrate voting power. A second proposal would allow adjournment of the meeting to solicit more proxies if support for Proposal 1 is initially insufficient.
Quoin Pharmaceuticals Ltd. (QNRX) announced that the U.S. FDA has granted Fast Track Designation to its investigational topical lotion QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment. This is the second Fast Track Designation for QRX003, following an earlier designation for Netherton Syndrome.
The company expects to initiate a Phase 2/3 study in Peeling Skin Syndrome in the second half of 2026, enrolling up to 12 pediatric and adult patients in the U.S. and Europe, with QRX003 applied twice daily over 48 weeks and an interim review at 24 weeks. Quoin is targeting potential approval of QRX003 for Peeling Skin Syndrome in 2028 and reports over 15 months of treatment in an investigator-led pediatric study with improved severity endpoints and no reported adverse events.